Rein Therapeutics (RNTX)
NASDAQ:RNTX
Want to see RNTX full AI Analyst Report?
RNTX Stock Chart & Stats
$1.26
--
Market closed
$1.26
--
Day’s Range― - ―
52-Week Range$0.95 - $2.21
Previous CloseN/A
VolumeN/A
Average Volume (3M)228.95K
Market Cap
$82.94M
Enterprise Value$27.66M
Total Cash (Recent Filing)$4.45M
Total Debt (Recent Filing)$4.92M
Price to Earnings (P/E)―
Beta1.27
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding85,539,030
10 Day Avg. Volume262,542
30 Day Avg. Volume228,948
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.74
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap0.33
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.29
Forecast
1Y Price Target
$10.00Price Target Upside693.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Extended Cash Runway From Equity RaiseA $50M underwritten equity offering materially extends the company's operating runway into 2028, reducing near-term liquidity risk and giving management time to advance clinical milestones. This structural capital reduces the frequency of urgent financing needs over the medium term.
Modest LeverageLow absolute debt versus equity provides financial flexibility and lowers bankruptcy and interest servicing risk. Modest leverage supports the firm's ability to pursue clinical programs or secure non-dilutive funding without immediate heavy burden from fixed financial obligations.
Focused Clinical-stage AssetA focused pipeline with an active Phase 2 asset (LTI-03) concentrates resources on a clear, value-driving milestone. Successful clinical progress or partnering around a single pulmonary program can create durable strategic optionality and attract longer-term collaborators or licensing deals.
Bears Say
No Revenue And Large LossesThe company reports no product revenue and sustained large net losses, meaning operations rely entirely on financing rather than internal cash generation. This structural deficit increases dependence on capital markets and makes long-term viability contingent on clinical success or continued funding.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow indicates the business cannot self-fund development activity. Even with burn improvement versus prior years, ongoing outflows require external capital to sustain trials and operations, raising execution and dilution risk over the medium term.
Shrinking Equity BaseA materially reduced equity base erodes the company’s financial cushion and magnifies the impact of future losses or write-downs. It heightens reliance on dilutive financings, can worsen borrowing terms, and weakens balance-sheet resilience to clinical setbacks or regulatory delays.
Rein Therapeutics News
RNTX FAQ
What was Rein Therapeutics’s price range in the past 12 months?
Rein Therapeutics lowest stock price was $0.95 and its highest was $2.21 in the past 12 months.
What is Rein Therapeutics’s market cap?
Rein Therapeutics’s market cap is $82.94M.
When is Rein Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Rein Therapeutics’s earnings last quarter?
Currently, no data Available
Is Rein Therapeutics overvalued?
According to Wall Street analysts Rein Therapeutics’s price is currently Undervalued.
Does Rein Therapeutics pay dividends?
Rein Therapeutics does not currently pay dividends.
What is Rein Therapeutics’s EPS estimate?
Rein Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rein Therapeutics have?
Rein Therapeutics has 85,539,030 shares outstanding.
What happened to Rein Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rein Therapeutics?
Currently, no hedge funds are holding shares in RNTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Rein Therapeutics
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
RNTX Stock 12 Month Forecast
Average Price Target
$10.00
▲(693.65% Upside)
Technical Analysis
―
Kezar Life Sciences
―
Vivos Therapeutics
―
OnKure Therapeutics
―
Rani Therapeutics Holdings
―
Ownership Overview
6.80% Insiders
4.22% Mutual Funds
33.57% Other Institutional Investors
51.36% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---